Subtype
Glioma
CI-CAN-00000935Explore in graph →
Non-malignant787 active trials5 approved drugs147 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00000935Explore in graph →
Clinical trials
2,805 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06496971 | A Prospective Pivotal Study to Evaluate the Efficacy and Safety of Avastin® Bevacizumab (BEV) With or Without Microbubble-mediated Focused Ultrasound (FUS-MB) Using NaviFUS System in Recurrent Glioblastoma Multiforme Patients | recruiting | Phase 3 | 32 | NaviFUS CorporationINDUSTRY | 1 | Apr 9, 2026 | clinicaltrials |
| NCT07134842 | A Study Assessing if it is Safe and Possible to Treat Brain Cancer Patients With Immunotherapy Before They Receive the Standard Treatment.(WinGlio-ipi) | recruiting | Phase 1 | 16 | University College, LondonOTHER |
| 1 |
| Apr 9, 2026 |
| clinicaltrials |
| NCT07301268 | GI-102 Alone or With Pembrolizumab Before Surgery for Treatment of Recurrent or Progressive IDH Wildtype Glioblastoma and IDH Mutated Grade 4 Astrocytoma | recruiting | Phase 2 | 36 | Mayo ClinicOTHER | 1 | Apr 8, 2026 | clinicaltrials |
| NCT02104310 | A Pilot Study Using 18F-DOPA PET-guided Radiotherapy in Gliomas | active not recruiting | — | 25 | Mayo ClinicOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT07488754 | Local, Targeted Therapy With Alpha Emitter [225Ac]Ac-DOTA-SP (TAT) In Newly Diagnosed Glioma (WHO G3-G4) | recruiting | N/A | 35 | Medical University of WarsawOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT07511725 | Prophylactic Regimen With Intrathecal Thiotepa in SVZ-positive or Meningeal-risk Glioblastoma(PRISM) | recruiting | Phase 2 | 38 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT03526250 | Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial) | completed | Phase 2 | 23 | National Cancer Institute (NCI)NIH | 2 | Apr 3, 2026 | clinicaltrials |
| NCT03678883 | 9-ING-41 in Patients With Advanced Cancers | active not recruiting | Phase 2 | 350 | Actuate Therapeutics Inc.INDUSTRY | 7 | Apr 3, 2026 | clinicaltrials |
| NCT07497373 | A Phase I Study to Evaluate the Safety and Tolerability of JL15003 Injection in Patients With Recurrent Glioblastoma(JL15003) | completed | Phase 1 | 17 | Jecho Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Apr 3, 2026 | clinicaltrials |
| NCT05789394 | Allogenic Adipose-Derived Mesenchymal Stem Cells for the Treatment of Recurrent Glioblastoma or Recurrent Astrocytoma in Patients Undergoing Craniotomy | recruiting | Phase 1 | 20 | Mayo ClinicOTHER | 1 | Apr 2, 2026 | clinicaltrials |
| NCT07417761 | Tuvusertib in Astrocytoma With ATRX Mutation(TUVASTRAT) | recruiting | Phase 2 | 56 | Grupo Español de Investigación en NeurooncologíaOTHER | 1 | Apr 2, 2026 | clinicaltrials |
| NCT07506239 | Efficacy of Laser Interstitial Thermal Therapy in Young Persons With Low-grade Glioma | recruiting | N/A | 40 | University of California, San FranciscoOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT05986851 | Azeliragon in MGMT Unmethylated Glioblastoma | active not recruiting | Phase 2 | 30 | Cantex PharmaceuticalsINDUSTRY | 1 | Mar 31, 2026 | clinicaltrials |
| NCT06650605 | Phase 1 Open-label Study of 123I-ATT001 in Subjects With Relapsed Glioblastoma(CITADEL-123) | completed | Phase 1 | 7 | Theragnostics LtdINDUSTRY | 1 | Mar 31, 2026 | clinicaltrials |
| NCT03194971 | NovoTTF Treatment Signatures in Glioblastoma Patients at Autopsy | completed | — | 20 | Medical College of WisconsinOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT03596086 | HSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBM | recruiting | Phase 1 / Phase 2 | 62 | David Baskin MDOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT03603405 | HSV-tk and XRT and Chemotherapy for Newly Diagnosed GBM | recruiting | Phase 1 / Phase 2 | 62 | The Methodist Hospital Research InstituteOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT03663725 | Treatment Intensification With Temozolomide in Adults With a Glioblastoma(StrateGlio) | active not recruiting | Phase 3 | 486 | Centre Oscar LambretOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT04471844 | Pivotal, Randomized, Open-label Study of Optune® (Tumor Treating Fields) Concomitant With RT & TMZ for the Treatment of Newly Diagnosed GBM(EF-32) | completed | N/A | 981 | NovoCure Ltd.INDUSTRY | 11 | Mar 30, 2026 | clinicaltrials |
| NCT04559230 | Sacituzumab Govitecan in Recurrent Glioblastoma | recruiting | Phase 2 | 32 | The University of Texas Health Science Center at San AntonioOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT07431216 | A Phase 1b/2a Study to Evaluate the Safety, Pharmacokinetics, and Objective Response of STAR-001 (LP-184) in Combination With Spironolactone in Supratentorial Glioblastoma at First Progression | not yet recruiting | Phase 1 / Phase 2 | 68 | Starlight Therapeutics Inc.INDUSTRY | 0 | Mar 30, 2026 | clinicaltrials |
| NCT07499141 | Use of Fluorescence in Gliomas(UFGAG) | completed | — | 41 | Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo di AlessandriaOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT03605550 | A Phase 1b Study of PTC596 in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma and High Grade Glioma | active not recruiting | Phase 1 | 64 | Nationwide Children's HospitalOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT04019002 | Hyperpolarized Carbon-13 (13C) Pyruvate Imaging in Patients With Glioblastoma | completed | Phase 1 | 17 | Susan ChangOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT04801147 | Immunotherapy With Autologous Tumor Lysate-Loaded Dendritic Cells In Patients With Newly Diagnosed Glioblastoma Multiforme(DENDR1) | completed | Phase 1 / Phase 2 | 76 | Fondazione I.R.C.C.S. Istituto Neurologico Carlo BestaOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT01743950 | A Phase II Study of Pulse Reduced Dose Rate Radiation Therapy With Bevacizumab | terminated | Phase 2 | 49 | University of Wisconsin, MadisonOTHER | 1 | Mar 25, 2026 | clinicaltrials |
| NCT02586857 | A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM) | active not recruiting | Phase 1 / Phase 2 | 24 | Acerta Pharma BVINDUSTRY | 1 | Mar 25, 2026 | clinicaltrials |
| NCT04574856 | Multiparametric MR-Guided High Dose Adaptive Radiotherapy With Concurrent Temozolomide in Patients With Newly Diagnosed Glioblastoma | active not recruiting | Phase 2 | 30 | University of Michigan Rogel Cancer CenterOTHER | 1 | Mar 25, 2026 | clinicaltrials |
| NCT07492836 | Hypofractionated Radiotherapy Plus Temozolamide in Patients Younger Than 70 Years With Glioblastoma(HipoGBM) | not yet recruiting | N/A | 10 | Hospital do CoracaoOTHER | 0 | Mar 25, 2026 | clinicaltrials |
| NCT02286167 | Glioma Modified Atkins-based Diet in Patients With Glioblastoma(GLAD) | completed | N/A | 25 | Wake Forest University Health SciencesOTHER | 1 | Mar 24, 2026 | clinicaltrials |
| NCT05413304 | Abemaciclib Neuropharmacokinetics of Diffuse Midline Glioma Using Intratumoral Microdialysis | active not recruiting | Phase 1 | 1 | National Cancer Institute (NCI)NIH | 1 | Mar 24, 2026 | clinicaltrials |
| NCT06482905 | Safety and Efficacy Study of TX103 CAR-T Cell Therapy for Recurrent or Progressive Grade 4 Glioma. | recruiting | Phase 1 | 52 | Tcelltech Inc.INDUSTRY | 2 | Mar 24, 2026 | clinicaltrials |
| NCT06763965 | Evaluating the Safety and Efficacy of BioTTT001 in Patients With Recurrent/Progressive High-grade Glioma. | enrolling by invitation | Phase 1 / Phase 2 | 30 | Beijing Bio-Targeting Therapeutics Technology Co., LtdINDUSTRY | 1 | Mar 23, 2026 | clinicaltrials |
| NCT07089758 | A Study for Cerebral Open Flow Microperfusion | not yet recruiting | N/A | 6 | Mayo ClinicOTHER | 1 | Mar 23, 2026 | clinicaltrials |
| NCT07126990 | Clinical Study of a Novel Oncolytic Virus Ad-TD-nsIL12 in the Treatment of Primary High-grade Glioma | enrolling by invitation | Phase 1 / Phase 2 | 40 | Xiaorong WuINDUSTRY | 1 | Mar 23, 2026 | clinicaltrials |
| NCT03551249 | Assessment of Safety and Feasibility of ExAblate Blood-Brain Barrier (BBB) Disruption | completed | N/A | 20 | InSightecINDUSTRY | 1 | Mar 20, 2026 | clinicaltrials |
| NCT04417088 | Exablate Blood-Brain Barrier Disruption for the Treatment of rGBM in Subjects Undergoing Carboplatin Monotherapy | completed | Phase 1 / Phase 2 | 28 | InSightecINDUSTRY | 1 | Mar 20, 2026 | clinicaltrials |
| NCT04458272 | A Study of DS-1001b in Patients With Chemotherapy- and Radiotherapy-Naive IDH1 Mutated WHO Grade II Glioma | active not recruiting | Phase 2 | 25 | Daiichi Sankyo Co., Ltd.INDUSTRY | 1 | Mar 20, 2026 | clinicaltrials |
| NCT05733572 | Safety and Efficacy of the PAINLESS Nerve Growth Factor CHF6467 in Optic Pathway Glioma (OPG)(NGF-OPG) | active not recruiting | Phase 2 | 36 | Benedetto FalsiniOTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT07481721 | IL13Rα2 CAR-T Cells Secreting Anti-PD-L1 Antibody for Recurrent Malignant Glioma(APIC-RG) | not yet recruiting | Phase 1 | 24 | Ming YangOTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT02115074 | Safety of Fluvastatin-Celebrex Association in Low-grade and High Grade Optico-chiasmatic Gliomas(FLUVABREX) | completed | Phase 1 | 20 | Centre Oscar LambretOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT02375841 | Coping With Glioblastoma: A Study of Communication Between Physicians, Patients, and Caregivers | active not recruiting | — | 309 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT03478462 | Dose Escalation Study of CLR 131 in Pediatric Relapsed/Refractory Malignant Tumors Including Neuroblastoma and Sarcomas(CLOVER-2) | active not recruiting | Phase 1 | 30 | Cellectar Biosciences, Inc.INDUSTRY | 3 | Mar 18, 2026 | clinicaltrials |
| NCT04655404 | A Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma With NTRK Fusion | recruiting | Early Phase 1 | 15 | Nationwide Children's HospitalOTHER | 5 | Mar 18, 2026 | clinicaltrials |
| NCT05500391 | Assessment of Compliance With Monitoring Conducted by a Physician in Person or by a Nurse in Remote Monitoring(SUR-CAN) | recruiting | Phase 2 | 88 | Centre Oscar LambretOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT05577416 | A Study of AB-218 in Patients With IDH1 Mutated Low Grade Glioma(AB-218-IIT-201) | completed | Early Phase 1 | 14 | Melbourne HealthOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT05610891 | Novel Targeted Radiotherapy in Pediatric Patients With Inoperable Relapsed or Refractory HGG | active not recruiting | Phase 1 | 50 | Cellectar Biosciences, Inc.INDUSTRY | 2 | Mar 18, 2026 | clinicaltrials |
| NCT07480941 | Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma(DUAL-CAR-NK-GB) | recruiting | Phase 1 | 36 | Beijing BiotechINDUSTRY | 1 | Mar 18, 2026 | clinicaltrials |
| NCT04943848 | rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMG | recruiting | Phase 1 | 36 | Ann & Robert H Lurie Children's Hospital of ChicagoOTHER | 1 | Mar 17, 2026 | clinicaltrials |
| NCT05393258 | Temporally-modulated Pulsed Radiation Therapy (TMPRT) After Prior EBRT for Recurrent IDH-mutant Gliomas | completed | N/A | 13 | Washington University School of MedicineOTHER | 1 | Mar 17, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Apr 9, 2026source: clinicaltrials